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Purpose: Safe and prolonged drug delivery to the retina is a key obstacle to overcome in the development of new medicines
aimed at treating progressive retinal disease. We took advantage of the ability of embryonic stem cells to survive long-
term in foreign tissue and used these cells to deliver neuroprotectant molecules to the retina of the rhodopsin TgN S334ter-4
rat model of retinitis pigmentosa (RP).
Methods: Mouse embryonic stem (mES) cells, derived from the pluripotent embryonic stem cell line E14TG2a, were
genetically engineered to oversecrete the glial cell-derived neurotrophic factor (GDNF). Cell suspensions, containing
approximately 200,000 cells and expressing approximately 35ng/106 cells/24 h GDNF, were injected into the vitreous
cavity  of  TgN  S334ter  rat  eyes  at  postnatal  day  21  (P21)  without  immunosuppression.  Histological  and
immunofluorescence imaging was used to evaluate photoreceptor survival up to P90. Local (vitreous) and systemic (serum)
concentrations of GDNF were determined and ocular side effects were monitored.
Results: Green fluorescent protein (GFP)-expressing mES cells were observed on the inner limiting membrane of the
retina in retinal flatmounts up to P90. In cryostat sections at P45, some GFP-expressing cells had integrated into the inner
retina, but did not migrate into the outer nuclear layer. After an initial lag period, the photoreceptor cell counts were
significantly higher (p≤0.05) in animals treated with GDNF-secreting mES cells than in untreated animals, principally in
the peripheral retina. Several adverse side effects such as tractional detachments and areas of hyperplasia were seen in a
minimal number of treated eyes. Abnormally high levels of GDNF in the peripheral circulation were also observed.
Conclusions: ES cells engineered to secrete GDNF exerted a neuroprotective effect for at least three months on retinal
structure in the TgN S334ter rat model of retinal degeneration. Immunosuppression was not required for this. Several
adverse effects were identified which require further investigation to make cell-based delivery of neuroprotection a viable
clinical strategy.
Apoptotic  cell  death  is  a  central  process  in  the
pathophysiology of a diverse number of diseases of the central
nervous system (CNS). In the eye, apoptotic cell death is a key
factor  in  many  blinding  retinal  diseases,  such  as  retinitis
pigmentosa (RP) [1], and also the atrophic (dry) form of age-
related macular degeneration [2]. Such retinal diseases are
among the most common causes of blindness in the developed
world [3]. Any therapeutic process that can impede retinal cell
death could therefore have a major impact on the prevalence
of  blindness.  Over  the  last  decade  the  concept  of
neuroprotection, particularly aimed at the CNS, has emerged
with  the  goal  of  inhibiting  apoptotic  cell  death  through
pharmacological means [4-6].
Pioneering work by Faktorovich and coworkers revealed
delayed photoreceptor degeneration in the Royal College of
Surgeons rat using basic fibroblast growth factor (bFGF) [7].
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Since then, considerable evidence has emerged to show that
a range of neurotrophic (survival) growth factors can inhibit
retinal degeneration in several animal models [8,9]. These
include  glial-derived  neurotrophic  factor  (GDNF)  [10,11],
brain-derived  neurotrophic  factor  (BDNF)  [12],  ciliary
neurotrophic factor (CNTF) [12,13], lens epithelium-derived
growth  factor  (LEDGF)  [14],  pigment  epithelium-derived
factor  (PEDF)  [15],  and  rod-derived  cone  viability  factor
(RdCVF) [16]. Clinical studies to date however have reported
mixed results. Significant progress with CNTF use in outer
retinal degeneration patients has been reported [17,18], but
less success has been seen using memantine (an N-methyl D-
aspartate-type [NMDA-type] glutamatergic channel blocker
with neuroprotective action [19]) in patients with ganglion
cell disease [20].
Most neurotrophic agents that have been studied in retinal
disease are either too large to cross the blood–retinal barrier
(BRB) [21] or are associated with unacceptable systemic side
effects. Thus direct delivery to the eye is regarded as the only
practical way to deliver neuroprotection. This would however
necessitate  repeated  and  frequent  intraocular  injections.
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962Several long-term delivery methods have been proposed to
manage this problem. These include: slow release capsules
[13,22]; coating onto beads [10,23]; transfecting retinal cells
in  situ  to  secrete  neuroprotectant  [24];  and  trans-scleral
delivery of drug [25,26]. In addition cell-based delivery of
neuroprotectant has also been investigated [27-29], although
the best cell to use has yet to be established. Therefore, in this
study we undertook preliminary, “proof-of-principle” work to
determine  whether  genetically  modified  embryonic  stem
cells, injected into the vitreous cavity, could be useful in the
long-term delivery of neuroprotectant in retinal degeneration.
In particular we specifically assessed the likely limitations of
this technology.
METHODS
Engineering of mammalian expression vector, pGDNF.GFP:
We engineered a plasmid (that we named ‘pGDNF.GFP’)
through several cloning steps to constitutively express GFP
and  GDNF.  The  open  reading  frame  of  human  GDNF
(AY893733; obtained from human cDNA sequence; Dana-
Farber/Harvard Cancer Centre DNA Resource) was amplified
by PCR with a reverse primer containing a stop codon. In
addition  the  primers  contained  XbaI  and  PacI  linkers  to
facilitate directional cloning. This PCR product was digested
with XbaI and PacI and subcloned into the polylinker of the
mammalian  expression  vector,  pCAβ-linker1  internal
ribosome  entry  site  (IRES).GFP  (a  gift  from  Caroline  J.
Formstone,  King’s  College  London,  UK).  Expression  of
GDNF is driven by the chicken β-actin promoter under the
influence  of  the  cytomegalovirus  enhancer  [30],  and
expression of GFP is from the IRES translation initiation
sequence.  A  puromycin  resistance  gene  cassette  was  also
amplified by PCR from a 3′HPRT targeting vector [31] and
cloned into the SapI site of the final construct, pCAbeta linker
1  IRES.GFP/hGDNF  puro  (abbreviated  to  pGDNF.GFP).
Cloned regions were sequenced to ensure plasmid integrity.
Mouse embryonic stem cell culture: We elected to transfect
the expression vector into mouse embryonic stem (mES) cells
because of the lack of availability of sufficiently characterized
rat ES cells for ex vivo gene therapy. E14TG2a cells (a gift
from  Dr.  Andrew  Smith,  University  of  Edinburgh,  UK)
originally  derived  from  129  strain/Ola  mice  [32]  were
cultured in the absence of a fibroblast feeder layer on 0.1% w/
v  gelatinized  6  cm  plates  in  complete  media  (knockout
Dulbecco's  modified  eagle  medium  [DMEM];  Invitrogen
Ltd., Paisley, UK), supplemented with 15% fetal calf serum
(Cambrex,  Verviers,  Belgium),  1%  penicillin  and
streptomycin,  20  mM  L-glutamine,  0.1  mM  β-
mercaptoethanol, and 50 U leukemia inhibitory factor (LIF;
Chemicon Europe Ltd, Chandlers Ford, UK). Cultures were
maintained at 37 °C with 5% CO2 with media replacement
every 24 h.
Stable  transfections  of  GDNF  secreting  mES  cells:  The
pGDNF.GFP construct was transfected into mES cells by
electroporation. Next, mES cells were harvested, then washed
in PBS, which contained 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4,  and  1.47  mM  KH2PO4,  pH  of  7.4.  Cells  were
resuspended in PBS at a concentration of 2.5×107 cells in
600 μl. The cell suspension was mixed with 50 μg of SalI
linearized  pGDNF.GFP  plasmid  DNA,  placed  in  0.4  cm
electroporation cuvettes, and electroporated in a gene pulser
(Bio-Rad, Hemel Hempstead, UK) at 0.8 Kv, 3 μF for 0.2
msec. Cells were resuspended in complete media and plated
at a density of 2.5×106/10 cm dish. After 24 h the media was
replaced  with  complete  media  containing  puromycin  at
0.4 μg/ml and cells remained in selection for 15 days when
colonies became visible. Resistant ES cell colonies (192 in
total) were placed into 96 well plates and expanded for five
days. Each colony was then replica plated (1:4), and a week
later, were assessed for GDNF secretion by Enzyme-linked
immunosorbent assay (ELISA) of supernatant.
Immunocytochemistry:  Cells  were  fixed  in  4%  PFA
(paraformaldehyde) and then, permeabilised in 0.2% Triton
X-100/PBS (PBS composition: 137 mM NaCl; 2.7 mM KCl;
4.3 mM Na2HPO4; 1.47 mM KH2PO4; pH of 7.4), blocked for
2 h at room temperature in 2% normal serum/0.5% BSA
(blocking buffer) and then incubated with primary antibody
for 16 h at 4 °C in blocking buffer [33]. Rabbit anti-GFP
(Invitrogen) was used to check gene expression in transfected
cells and rabbit anti-human OCT4 (Sigma-Aldrich Company
Ltd.,  Gillingham,  UK)  was  used  to  confirm  pluripotency.
After washing 3 times in blocking buffer, cells were then
incubated with a 1:1000 dilution of a secondary antibody in
blocking  buffer,  conjugated  to  alkaline  phosphatase  (goat
anti-rabbit IgG) for 30 min at room temperature. Cells were
washed three times in PBS-Tween-20 and then developed
with  4-Chloro-2-methylbenzenediazonium/3-Hydroxy-2-
naphthoic acid 2,4-dimethylanilide phosphate tablets (Fast
Red TR/AS-MX Napthol phosphate; Sigma-Aldrich). Cells
were mounted with Hydromount and visualized under light
microscopy.  For  immunocytochemistry  in  tissue  sections,
GFP  expression  was  examined  using  a  GFP-fluorescein
isothiocyanate (FITC) antibody (Abcam plc, Cambridge, UK)
and epifluorescence microscopy.
Disease model: The primary aim of the study was to determine
the  effectiveness  and  safety  of  stem  cell  delivery  of
neuroprotectant (in this case GDNF) in an in vivo model. We
therefore undertook studies in a model where GDNF had
already been shown to have a reproducible neuroprotective
effect. Only limited studies of GDNF effectiveness have been
undertaken in mouse models of retinal degeneration: rd1 [10,
34] and Periph2 [11]. We did not consider either of these
models to be optimal for our study. One study of GDNF-
releasing  microspheres  showed  only  brief  and  limited
effectiveness in the rd1 mouse [10], and another study of
subretinal injection of GDNF only resulted in benefit in 4 of 10
rd1 retinas [34]. In addition, GDNF expression in Periph2
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963mice had little effect unless combined with gene replacement
therapy [11].
Conversely,  GDNF  has  been  shown  to  effectively
neuroprotect in the S334ter rat well beyond the postnatal day
21 (P21) time point. TgN S334ter were donated by Professor
Matt LaVail (University of California at San Francisco, San
Francisco,  CA)  [35].  During  the  study,  all  animals  were
housed in standard cages and given food and water ad libidum
while being maintained on a 12-h light/dark schedule. All
work was performed with adherence to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research
and local Ethical Committee regulations. GDNF has been
shown to be an effective neuroprotectant in this model [36].
The insertion of a premature termination codon [37] leads to
the translation of a truncated protein lacking the last 15 amino
acids, similar to abnormalities of the C-terminal domain found
in many human cases of RP [38].
Cell  injections:  Expanded  E14TG2a  mES  cells  were
resuspended in PBS to give a final concentration of 50,000
cells/μl. A Hamilton syringe was used to inject 4 μl of the cell
suspension (2×105 cells) into the vitreous cavity of one eye,
through an entry site 1–2 mm behind the limbus of P21 TgN
S334ter rats. In total three groups of animals were studied.
One group of animals was treated with GDNF secreting mES
cells (n=34), one group with unmodified mES (n=15), and a
final  group  received  sham  injections  of  PBS  (n=19).  No
animals underwent immunosuppression.
Histological assessment of rat retina treated with GDNF-mES
cells: Animals were euthanized by CO2 asphyxiation. Eyes
were enucleated and marked at the 12 o’clock position, using
a black nylon stitch for orientation. For cryostat sectioning,
eyes were immersed in 4% PFA for 1 h, cryopreserved in 30%
sucrose overnight, snap frozen and then embedded in OCT
compound.  Either  5  μm  sagittal  or  coronal  sections  were
stained with GFP-FITC antibody and DAPI. The sections
were examined with fluorescence microscopy, and montages
were made in Photoshop 4.0. Eyes for retinal flatmounts were
immersed for 1 h in 4% PFA. The anterior segment was then
removed and the eyecup immersed for a further 1 h. The
orientation mark was transferred to the retina by cutting a
notch and then radial cuts were made toward the optic nerve
using sharp scissors. The retina was gently teased off the eye
cup as a single piece of tissue, and transferred to a microscope
slide, where it was positioned. Several drops of Hydromount
were  placed  on  the  tissue  and  a  coverslip  added.  GFP-
expressing  mES  cells  were  visualized  by  confocal
microscopy.  Eyes  that  would  be  used  for  counting
photoreceptor  nuclei  were  immersed  in  half  strength
Karnovsky's  fixative  for  1  h,  and  the  anterior  segment
removed by excision at the ora serata. Posterior segments were
embedded in paraffin, cut sagitally to a thickness of 5 μm, and
counterstained with hematoxylin and eosin.
Photoreceptor cell counting: To standardize photoreceptor
nuclei  counting  from  different  eyes,  we  only  employed
sagittal sections that included the optic nerve. Images were
overlaid with a 300 μm-length rectangular template using
Canvas (ACD Systems, Miami, FL) software. This template
was  positioned  at  four  predetermined  coordinates  to  give
counts  from  two  central  (behind  the  equator)  and  two
peripheral (in front of the equator) coordinates [39]. These
four images for each eye were then imported into Photoshop,
and  photoreceptor  nuclei  in  the  outer  nuclear  layer  were
labeled with overlaying spots. An exported JPEG of this layer
of spots was then counted in ImageJ v 1.37.software to give
the total number of outer nuclear layer nuclei in each grid.
ELISA assays: The concentration of GDNF protein in tissue
culture  supernatant,  rat  serum,  and  rat  vitreous  was
determined with the GDNF Emax® ImmunoAssay System
(Promega Ltd., Southampton, UK), which was used according
to manufacturer’s instructions. Briefly, a 96 well plate was
coated with anti-GDNF monoclonal antibody. The samples
were then applied to the plate overnight, washed three times
with wash buffer (20mM Tris-HCl pH 7.6; 150mM NaCl;
0.05% (v/v) Tween® 20), and incubated with a polyclonal
antibody to GDNF. Samples were incubated with a secondary
anti-chicken  immunoglobulin  Y  antibody  conjugated  to
horseradish  peroxidase  and  detected  using  a  chromogenic
substrate. The color change was measured at 450 nm using a
spectrophotometer.
Statistical analysis: Data was collected from eyes treated with
intravitreal injections of either GDNF-secreting mES cells,
unmodified  mES  cells,  or  vehicle  only.  Results  were
compared as mean±standard error of the mean (SEM). Nuclei
counts  were  compared  between  groups  using  the  non-
parametric Mann–Whitney test (Minitab statistical software
pack version 15.0) to account for comparison between groups
of different size. Statistical significance was set as p≤0.05. For
GDNF levels in serum and vitreous samples a paired Student
t-test was used. Data from each time point in control mES cell-
injected groups was compared to data from GDNF-mES cell-
treated groups and analyzed for statistical significance.
RESULTS
GDNF-secreting mES cell line production: Several rounds of
transfection  with  pGDNF.GFP  were  performed  with
increasing concentrations of puromycin as a selectable marker
for integration of the plasmid. Presence of GFP expression in
mES cells in culture compared to controls was confirmed by
immunocytochemistry (Figure 1A,B). mES cell clones were
also screened for GDNF secretion into supernatant by ELISA.
GDNF was quantified using regression analysis based on the
standard curve plotted from analysis of known concentrations
of  a  GDNF  standard.  In  the  first  attempt,  nine  colonies
(0.4  μg/ml  puromycin)  were  generated  ranging  in  GDNF
secretion of 6.45–10.2 ng/GDNF/106 cells/24 h. Subsequently
increasing puromycin selection to 2 μg/ml generated four
clones with GDNF secretion into supernatant ranging from
11.1 to 36.0 ng/GDNF/106 cells/24 h.
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964Assessment of pluripotency in GDNF-secreting mES cells:
The Oct4 gene encodes a transcription factor that is expressed
in mES cells. Oct4 is crucial for the maintenance of embryonic
cell pluripotency. Downregulation of Oct4 would indicate cell
differentiation  with  possible  loss  of  the  tissue  integration
characteristics  of  pluripotent  ES  cells  [40].
Immunocytochemistry in clumps of mES cells, expressing 36
ng GDNF/106 cells/24 h, showed Oct4 expression in all cells
(Figure 1C,D). This established that this cell line remained
pluripotent in tissue culture.
mES cell survival within retinal tissue: Retinal flat mounts
from eyes at P50, P70, and P90 were used to observe mES cell
survival and cell distribution over time. GFP-expressing cells
did not appear to be distributed uniformly across the retinal
surface (Figure 2). Interestingly, at all time points studied, the
majority of GFP-expressing cells were found to localize to the
peripheral retina, although most retinas did have some cells
centrally as well. By P90, clumping of autofluorescence was
less apparent and a more diffuse fluorescence was evident
(Figure 3). This could have been due to cell migration from
the surface into the substance of the retina.
In vivo integration of mES cells into retinal tissue: In TgN
S334ter  eyes  treated  with  GDNF-secreting  mES  cells,
fluorescence imaging of retinal sections identified distinct,
elongated, regions of GFP-staining cell clumps adherent to the
inner limiting membrane (Figure 4). In several instances the
GFP-staining  cells  could  be  seen  traversing  the  inner
plexiform  layer  to  line  the  boundary  between  the  inner
plexiform layer and the inner nuclear layer (Figure 4C). We
did not see integration into the outer nuclear layer, consistent
with  observations  made  by  others  [41-43].  Sections  from
untreated TgN S334ter eyes or those injected with control
mES  cells  exhibited  fluorescence  only  within  the  retinal
pigmented epithelium or, weakly, within the photoreceptor
outer segments (Figure 4D). Due to lipofuscin accumulation
autofluorescence  is  a  well  known  feature  of  the  retinal
pigment epithelial cells and is a result of aging or retinal
degeneration. Autofluorescence is also often detectable in the
outer segments due to the tightly packed membranes (personal
communication,  John  Flannery,  University  of  California,
Berkeley, San Francisco, CA).
Histological rescue: Eyes from the three treatment groups
(GDNF-mES  cells,  unmodified  mES  cells,  sham  PBS
injection)  were  sectioned  and  outer  nuclear  layer
(photoreceptor) cell counts undertaken. When data from all
retinal coordinates for all time points were pooled together for
GDNF-secreting  mES  cell-treated  retina  versus  sham
controls,  a  statistically  significant  difference  was  seen
suggesting  a  relative  preservation  of  photoreceptors  with
GDNF-secreting  mES  cells  (p<0.001).  However,  it  was
evident that this relative preservation of nuclei was mostly
from counts pooled from peripheral coordinates (p<0.001)
rather  than  from  counts  pooled  from  central  coordinates
(p=0.15). At individual time points, statistically significant
peripheral retina preservation was seen at P50, P70, and P90
(p<0.05). In comparison for central retina, preservation of cell
nuclei was only statistically significant at P70 (p<0.05; Figure
5). No statistically significant difference was seen when data
Figure 1. GFP and Oct4 expression in
mES  cells  transfected  with  pGDNF.
Cells  expressing  this  GDNF  plasmid
also  express  fluorescent  protein  GFP
and  will  appear  red  colored  when
exposed to GFP antibody. A: Control
experiment, no red staining if mES cells
are not exposed to anti-GFP antibody.
B:  Immunostaining  of  mES  cells  in
culture  using  an  anti-GFP  antibody
gives cells a red coloration confirming
GFP  cell  expression.  C:  Control
experiment, no red staining if mES cells
are not exposed to anti- OCT4 antibody.
D: Cells immunostained using an anti-
human  OCT4  (POU5F1)  antibody
appear  red,  confirming  Oct4  cell
expression  and  establishing  cell
totipotency.
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965from unmodified mES cell-treated animals was compared
with sham-treated controls, suggesting that the preservation
of  outer  nuclear  layer  cells  was  not  due  to  an  inherent
neuroprotective effect of mES cells.
Local ocular adverse effects: No systemic adverse event was
recorded after intravitreal injection. However, several ocular
side effects were observed (Table 1). Of 68 injections, one eye
(treated with sham injection) had a severe, purulent discharge
which  was  assumed  to  be  an  endophthalmitis.  Other  side
effects included lens opacities (8%), total retinal detachment
(3%), and minor tractional detachments in 5% of cases. None
of  these  adversely  affected  eyes  were  used  in  cell  count
experiments. Several eyes exhibited areas of focal thickening
of outer nuclear layer of the retina relative to surrounding
areas. These were often seen to be over 20 cells thick with
sharply defined boarders. This is more than would be expected
in  age-matched  wild-type  or  TgN  S344ter  eyes  at
corresponding retinal coordinates [39,44]. These appeared to
represent areas of hyperplasia and did not occur in the inner
nuclear or ganglion cell layers.
In vivo measurement of GDNF concentration in ocular tissue
and  blood:  To  investigate  potential  long-term  systemic
consequences to exposure to elevated levels of GDNF, the
concentration of GDNF was determined in blood and vitreous
samples  from  wild-type,  untreated,  control,  and  treated
animals  at  three  different  time  points.  ELISA  results
suggested that compared to control eyes (mES cells only),
treatment  with  GDNF-secreting  mES  cells  significantly
increased  vitreous  levels  as  might  be  expected  after
intravitreal injection (range 6–16 fold over the three time
points;  p<0.01).  However,  GDNF  levels  were  also
significantly increased in serum samples (range 10–12 fold;
p<0.001), raising the serious possibility of systemic adverse
effects due to long-term exposure to GDNF (Table 2).
Figure 2. Composite flatmount images
from a single TgN S334ter treated retina
at  P70.  One  rat  eye  from  the  group
treated  with  intravitreal  glial-derived
neurotrophic  factor  (GDNF)-secreting
mouse embryonic stem (mES) cells at
P21.  Spots  of  increased
hyperfluorescence (white), indicative of
colonies  of  green  fluorescent  protein
(GFP)-expressing mES cells, are mainly
seen in the peripheral retina (arrows).
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966DISCUSSION
This  study  is  the  first  to  investigate  the  feasibility  of
embryonic  stem  cells  in  delivering  neuroprotectant  to  the
retina. The results demonstrated that mES cells, which were
engineered  to  secrete  GDNF  and  were  delivered  by
intravitreal injection to the TgN S334ter rat model of retinal
degeneration,  have  a  significant  effect  on  prolonging
photoreceptor survival compared to the parent cell line or
sham injection. This neuroprotective effect of GDNF was
evident for at least three months, suggesting that ES cells
could potentially be used as a tool to deliver neuroprotectant
to the degenerating eye.
GDNF is a member of the transforming growth factor
superfamily,  first  described  as  a  stimulant  of  survival  of
dopaminergic neurons in vitro [45]. Cell lines overexpressing
GDNF  have  neuroprotective  effects  in  models  of
neurodegenerative disorders such as Parkinson disease [46]
and Huntington’s disease [47]. Both GDNF and its receptors
are synthesized in the retina [48-50], an indication that this
growth factor has an innate neurotrophic role in this tissue.
Subretinal  injection,  slow-release  devices,  adenoviral
delivery, or cell-based delivery of GDNF have been shown to
delay photoreceptor loss in several different models of retinal
degeneration [10,13,27-29,34,36]. The cellular mechanism of
GDNF neuroprotection is however unresolved, as it has been
proposed  that  GDNF-induced  rescue  of  mutant
photoreceptors is an indirect effect mediated by retinal Müller
glial cells [51].
The  use  of  embryonic  stem  cells  to  deliver
neuroprotectant to the retina is a valid proposition, based upon
their remarkable ability to integrate and survive long-term in
mature and particularly diseased tissue [52]. In addition, it has
been  proposed  that  stem  cells  have  an  inherent
neuroprotective ability [41,43,53] that could be augmented by
genetic modification. Our data did not support this hypothesis
in  the  TgN  S334ter  retinal  degeneration  model  because
unmodified  mES  cells  alone  did  not  seem  to  afford  a
significant  protective  effect.  Remarkably,  the  relative
preservation of photoreceptor cells seen with GDNF-secreting
mES cells seemed to be regional in that most effect was seen
in  cell  counts  from  peripheral  retina.  This  appeared  to
correlate with the distribution of GDNF-secreting mES cells
seen  in  retinal  flat-mounts,  suggesting  that  GDNF
effectiveness is confined to the locality of secreting cells. This
Figure 3. Flatmount images of TgN S334ter rat retina treated with GDNF-secreting mES cells. Rows indicate assessments at time points P50,
P70, and P90. Columns, represent images from retina from A: upper nasal; B: upper temporal; C: central; D: lower nasal; E: lower temporal
areas. All rats were from the group treated with intravitreal glial-derived neurotrophic factor (GDNF)-secreting mouse embryonic stem (mES)
cells at P21. White spots indicative of colonies of green fluorescent protein (GFP)-expressing mES cells appear mainly on the surface of the
peripheral retina rather than central retina. As time progresses, clumps become more diffuse and ill-defined, suggesting either migration into
the retinal tissue or cell loss.
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967nonuniform  incorporation  of  cells  following  intravitreal
injection has been observed in several other studies [27,28,
42,43] and hence could limit the effectiveness of this approach
in human trials. In this context, it would be anticipated that
clinical  effectiveness  would  be  most  appreciated  when
neuroprotection significantly preserved the central (macula
containing) region.
It is not clear why mES cells tend to distribute toward the
peripheral retina, but this is the first report of this phenomenon
having a functional consequence. It could be in response to
signaling from a greater mass of degenerating photoreceptors
in  peripheral  retina  [54].  It  has  been  suggested  that
mesenchymal stem cells, for example, home in on damaged
tissue in a manner similar to the way leukocytes traffic from
the  blood  to  inflammatory  sites,  using  chemokines  and
adhesion molecules [55]. Another possibility is that this is a
physical  effect  after  injection  due  to  centrifugal  and
centripetal forces generated by eye movement, or it may be
secondary to saccadic eye movement-induced fluid currents
within the partially liquefied vitreous [56]. The complex shape
of the vitreous cavity has been modeled in fluid dynamics
studies. When exposed to saccadic eye movements, particles
injected into the fluid tend to flow toward the anterior vitreous,
just behind the lens regardless of their initial position [57].
Although this model does not fully reproduce the fibrillar
structure of the human vitreous, it does suggest that injected
cells would tend to accumulate anterior to the equator and
hence tend to concentrate in the peripheral retina. This could
have significant consequences for the distribution of effect of
any therapeutic agent injected into the vitreous.
Many  issues  need  to  be  addressed  before  translating
retinal neuroprotection into clinical practice. Among these is
the key concern of how best to deliver these drugs safely and
with  long-term  neuroprotective  effect.  In  this  study  we
Figure 4. Cryosections of TgN S334ter
rat retina studied at post-natal day 35.
All  sections  were  immunostained  for
green fluorescent protein (GFP; green)
and  retinal  cell  nuclei  were  counter-
stained blue with DAPI. A-C: Illustrates
images from rats from the group treated
at  post-natal  day  21  with  intravitreal
injection of GDNF-secreting (and GFP-
expressing)  mouse  embryonic  stem
cells  (mES  cells).  Plates  A-C
demonstrates  integration  of  GFP-
expressing  mES  cells  into  the  retina.
The asterisks mark clumps of mES cells.
Some are seen migrating (arrow in C)
from  the  innermost  retina  toward  the
outer retina, and extending between the
outer  nuclear  layer  (ONL)  and  inner
nuclear  layer  (INL).  D:  Illustrates  a
mock  injection  eye  from  the  group
treated  with  intravitreal  injection  of
sham  injection  of  PBS,  and  shows
autofluorescence in the retinal pigment
epithelium  and  photoreceptor  outer
segments  (arrowhead).  Abbreviations:
inner nuclear layer (INL); outer nuclear
layer  (ONL).  Scale  bars  represent  50
μm.
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TABLE 1. SIDE EFFECTS ASSOCIATED WITH INTRAVITREAL INJECTION INTO TGN S334TER RAT EYES.
Treatment Endophthalmitis Cataract Total retinal
detachment
Minor traction
detachment
GDNF-secreting mES cells (n=34) 0 2 0 2
Unmodified mES cells (n=15) 0 3 2 1
PBS sham injections (n=19) 1 0 0 0
Data from 68 treated eyes. These data show that complications were seen in rats regardless of the type of intravitreal injection
but that retinal side effects were seen only in rats treated with unmodified or GDNF-secreting mES cells. Abbreviations: glial-
derived neurotrophic factor (GDNF), mouse embryonic stem (mES), phosphate buffer solution (PBS).specifically noted the occurrence of adverse effects: tractional
retinal detachments, areas of outer nuclear layer hyperplasia,
and  abnormally  high  levels  of  GDNF  in  the  peripheral
circulation. Tractional retinal detachment, being a side effect
of GDNF per se, seems unlikely since a gene therapy approach
to GDNF delivery specifically revealed no such complications
[36]. These tractional detachments could be due to surgical
technique, although surgical trauma is relatively minor with
intravitreal injections. It is more likely to be due to mES cell
adhesion onto the vitreoretinal interface. The molecular and
cellular mechanisms resulting in this has not been determined,
but may induce a secondary inflammation and thus fibrosis.
Tractional detachments have not been detected in other cell-
based delivery studies that used immunosuppression [27,28].
When  GDNF-secreting  microspheres  were  used,  areas  of
retinal traction near microsphere aggregates were detected,
but no actual retinal detachment was observed [10]. Although
frequently  employed  in  cell  transplantation  research,
immunosuppression was not undertaken in this study for two
reasons. First, some studies suggest that immunosuppression
may not be needed when using embryonic stem cells [58],
although recently the immune privilege of embryonic stem
cells  has  been  questioned  [59].  Second,  the  study  was
designed more as a practical assessment of the technology
rather than a proof of principle experiment. Since long-term
immunosuppression  will  not  be  feasible  in  clinical
applications, it would seem unhelpful to base studies on its
use. However, immunoprivileged cells, e.g., those derived
from the subjects undergoing treatment, may be a practical
approach to employ in overcoming these immune reactions
[60].
Another adverse effect we observed was what appeared
to be focal areas of hyperplasia, similar to those seen in other
studies [10]. Dystrophic retina often appears to exhibit an
undulating  variation  in  outer  nuclear  layer  thickness  in
comparison  to  the  uniform  tapering  of  wild-type  retina
progressing from the posterior pole to the ora. However, we
found this hyperplasia to be more extreme than this. It could
represent local areas of enhanced cell preservation, correlating
with the “local” effectiveness of GDNF-secreting mES cells.
It might also represent areas of proliferation, although other
studies have specifically reported no indications of nerve or
glial cell mitogenesis induced by GDNF treatment [36]. This
observation could have significant consequences for clinical
trials and therefore warrants further investigation in larger
cohort studies, such as immunocytochemistry studies using
markers of retinal mitosis such as cyclin D1 [61].
No studies to date have reported on local or systemic
GDNF measurements in retinal degeneration models treated
with GDNF. Raised levels of GDNF in the vitreous would be
expected  with  a  cell-based  delivery  approach  as  the  cells
would secrete GDNF at the vitreoretinal interface. In addition
the high concentrations detected in the blood seem difficult to
explain from a cell source in the eye. It is possible that, rather
than GDNF leaking from the eye, actual GDNF-secreting
mES cells have made their way into the general circulation. It
is unclear what the likely consequences of this might be. One
study reports weight loss as a significant complication in a
human  clinical  trial  of  ventricular  injection  of  GDNF  in
patients  with  Parkinson  disease  [62].  Reduced  food
consumption was also observed in rhesus macaques receiving
infusion of GDNF into the putamen [63] and another study
reported cerebellar damage [64]. It has been assumed that little
would leak into the general circulation because of the blood–
retinal barrier, however this barrier is incomplete in retinal
dystophies [65]. Conversely, GDNF is thought to be a key
molecule in maintaining the blood–retina barrier [66]. Further
investigation is needed to study the cause and effect of this
adverse phenomenon.
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TABLE 2. GDNF CONCENTRATIONS IN VITREOUS AND SERUM SAMPLES
Sample                                     Wild-Type                                                              Untreated S334ter
Serum                         Vitreous  Serum
(pg/ml)
Vitreous
(pg/ml)
P50 12.8±1.6 21.3±19.4 23.5±3.8 16.5±7.8
P70 16.8±5.2 18.5±6.9 21.4±3.4 19.9±8.7
P90 14.0±4.1 3.8±1.0 28.5±11.0 9.2±10.1
Control S334ter                                                           Treated S334ter
Serum                         Vitreous                              Serum  Vitreous
 (pg/ml)
P50 29.4±4.9 18.3±7.2 *337.0±8.0 107.8±30.2**
P70 32.6±5.8 11.4±3.7 *333.0±79.8 181.1±32.1**
P90 22.1±7.2 14.2±6.3 *272.0±35.5 222.2±24.0**
Wild-type glial-derived neurotrophic factor (GDNF) levels in the serum and vitreous were compared to TgN S334ter treated
(GDNF-secreting mouse embryonic stem cells), TgN S334ter control (mouse embryonic stem cells only), or untreated S334ter
rats that were assessed at P50, P70, and P90 (n=3/time point). Data are presented as mean±SEM. The increase in serum
(*p<0.001) or vitreous (**p<0.01) GDNF levels in treated animals compared to control mES cell injections is significant.
time point
(pg/ml) (pg/ml)
(pg/ml) (pg/ml) (pg/ml)In summary, this study shows that mES cells engineered
to  deliver  GDNF  can  prolong  photoreceptor  survival.
However, complicating issues that have been observed would
need resolution before proceeding to clinical studies. This is
still  an  attractive  proposition,  however,  because  of  its
applicability to retinal disease of diverse etiologies. With the
arrival of clinical grade stem cells [67,68], produced on an
industrial scale, it is likely that embryonic stem cells, or their
derivatives will become an economically viable cell source
and therefore suitable for cell-based therapeutics needed to
support huge clinical demand.
Figure 5. Treated TgN S334ter rat retina photoreceptor cell nuclei
counts. Animals received injections at P21 and cell counts were
undertaken at periods up to P90. Graph A represents cell nuclei
counts from peripheral retina. Graph B presents cell nuclei counts
from posterior pole (central) retina. Cell counts were undertaken in
six  eyes  treated  with  glial-derived  neurotrophic  factor  (GDNF)-
secreting mouse embryonic stem (mES) cells, black bars; in another
8 eyes treated with unmodified mES cells, hatched bars; and in nine
eyes treated with sham injections, white bars. Data are presented as
the mean percentage of wild-type counts±SEM and analyzed for
statistical  significance  with  a  Mann–Whitney  test.  The  asterisk
indicates  p<0.05.  The  figure  demonstrates  that  preservation  of
photoreceptor cell nuclei was seen only in eyes treated with GDNF-
secreting mES cells and mostly in peripheral retina tissue.
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